AU3337297A - Fragments of leptin (ob protein) - Google Patents

Fragments of leptin (ob protein)

Info

Publication number
AU3337297A
AU3337297A AU33372/97A AU3337297A AU3337297A AU 3337297 A AU3337297 A AU 3337297A AU 33372/97 A AU33372/97 A AU 33372/97A AU 3337297 A AU3337297 A AU 3337297A AU 3337297 A AU3337297 A AU 3337297A
Authority
AU
Australia
Prior art keywords
leptin
fragments
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33372/97A
Other languages
English (en)
Inventor
Kamal A. Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU3337297A publication Critical patent/AU3337297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU33372/97A 1996-06-06 1997-06-04 Fragments of leptin (ob protein) Abandoned AU3337297A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GB9611775 1996-06-06
GB9618540 1996-09-05
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
GB9703493 1997-02-20
PCT/EP1997/002968 WO1997046585A2 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU71962/00A Division AU7196200A (en) 1996-06-06 2000-12-01 Fragments of leptin (ob protein)

Publications (1)

Publication Number Publication Date
AU3337297A true AU3337297A (en) 1998-01-05

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33372/97A Abandoned AU3337297A (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)

Country Status (15)

Country Link
EP (1) EP0912609A2 (xx)
JP (1) JP2000512137A (xx)
KR (1) KR20000016402A (xx)
CN (1) CN1221426A (xx)
AR (1) AR008765A1 (xx)
AU (1) AU3337297A (xx)
BR (1) BR9709529A (xx)
CA (1) CA2257240A1 (xx)
CZ (1) CZ397898A3 (xx)
IL (1) IL127153A0 (xx)
NO (1) NO985683D0 (xx)
NZ (1) NZ332879A (xx)
PL (1) PL330361A1 (xx)
TR (1) TR199802534T2 (xx)
WO (1) WO1997046585A2 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521496A (ja) 1998-07-28 2002-07-16 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー レプチン介在性遺伝子誘導
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
ATE300611T1 (de) 2000-05-22 2005-08-15 Vlaams Interuniv Inst Biotech Auf rezeptorgrundlage arbeitende screening- verfahren für protein wechselwirkungen
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
CA2535021A1 (en) 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Use of insp035 to treat fibrotic disease
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
KR20100093104A (ko) 2007-12-05 2010-08-24 아스트라제네카 아베 항비만제로서의 피페라진
WO2009071668A2 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Piperazine derivatives and their use as leptin receptor modulators
EP2313094A1 (en) * 2008-06-04 2011-04-27 AstraZeneca AB New pyridine derivatives as leptin receptor modulator mimetics
EP2313096A1 (en) * 2008-06-04 2011-04-27 AstraZeneca AB (Publ) New compounds v
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
WO2011143280A2 (en) * 2010-05-11 2011-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
JPH11501297A (ja) * 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
BR9709529A (pt) 1999-08-10
CN1221426A (zh) 1999-06-30
AR008765A1 (es) 2000-02-23
KR20000016402A (ko) 2000-03-25
WO1997046585A3 (en) 1998-04-23
NO985683L (no) 1998-12-04
NZ332879A (en) 2000-09-29
PL330361A1 (en) 1999-05-10
IL127153A0 (en) 1999-09-22
CA2257240A1 (en) 1997-12-11
WO1997046585A2 (en) 1997-12-11
EP0912609A2 (en) 1999-05-06
TR199802534T2 (xx) 1999-03-22
JP2000512137A (ja) 2000-09-19
CZ397898A3 (cs) 1999-04-14
NO985683D0 (no) 1998-12-04

Similar Documents

Publication Publication Date Title
AU3337297A (en) Fragments of leptin (ob protein)
AU5081298A (en) Surgical method and composition therefor
AU688210B2 (en) Recombinant obese (Ob) proteins
AU5721798A (en) Human mage-like protein
AU4922497A (en) Interleukin-18-receptor proteins
AU2517397A (en) Document of value
AU4467497A (en) Chaperone fragments
AU2548097A (en) Formulations of ob protein
AU6721696A (en) Cd44-like protein
AU5796298A (en) Secreted human proteins
AU3902297A (en) Two human nsp-like proteins
AU4750097A (en) Human reg i-gamma protein
AU5427398A (en) Cytoperfusion of tissue specimens
AU3451397A (en) Modified protein g and fragments thereof
AU4480697A (en) Human nm23-like protein
AU4824197A (en) Novel human lim proteins
AU3020899A (en) Compositions and methods for protein secretion
AU1538497A (en) Anti-gp46 antibodies and fragments thereof and their use
AU1750997A (en) Obesity protein formulations
AU2541397A (en) Tissue remodeling proteins
AU7584696A (en) Type ix collagen and fragments thereof
AU2245597A (en) Cross-linked polypeptide fragments of beta-galactosidase
AU1705197A (en) Obesity protein formulations
AU3640397A (en) Ob protein binding protein
AU2111997A (en) Assays using cross-linked polypeptide fragments of beta-galactosidase

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted